United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,269 shares of the business’s stock in a transaction on Thursday, October 13th. The shares were sold at an average price of $117.99, for a total value of $149,729.31. Following the transaction, the chief executive officer now owns 1,409 shares of the company’s stock, valued at approximately $166,247.91. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.52% on Monday, reaching $117.50. The company had a trading volume of 365,445 shares. The company has a 50 day moving average of $121.73 and a 200-day moving average of $116.02. The company has a market capitalization of $5.11 billion, a P/E ratio of 5.68 and a beta of 1.42. United Therapeutics Corp. has a 52 week low of $97.52 and a 52 week high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.22 by $1.33. The firm had revenue of $412.60 million for the quarter, compared to analysts’ expectations of $395.15 million. United Therapeutics Corp. had a return on equity of 49.30% and a net margin of 64.26%. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.55 EPS. Analysts predict that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for United Therapeutics Corp. (NASDAQ:UTHR)

UTHR has been the subject of a number of recent analyst reports. Argus restated a “hold” rating on shares of United Therapeutics Corp. in a report on Tuesday, August 23rd. Zacks Investment Research upgraded United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 price objective for the company in a report on Tuesday, July 26th. Cowen and Company reiterated a “buy” rating and issued a $144.00 target price on shares of United Therapeutics Corp. in a report on Friday, September 23rd. Wedbush reiterated an “outperform” rating and issued a $229.00 target price on shares of United Therapeutics Corp. in a report on Thursday, July 28th. Finally, Jefferies Group reiterated a “hold” rating and issued a $120.00 target price on shares of United Therapeutics Corp. in a report on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $137.09.

Institutional investors have recently modified their holdings of the stock. Smith Graham & Co. Investment Advisors LP bought a new position in shares of United Therapeutics Corp. during the third quarter valued at about $3,269,000. Nisa Investment Advisors LLC boosted its position in shares of United Therapeutics Corp. by 3.0% in the third quarter. Nisa Investment Advisors LLC now owns 16,997 shares of the biotechnology company’s stock valued at $2,007,000 after buying an additional 500 shares during the period. Fox Run Management L.L.C. bought a new position in shares of United Therapeutics Corp. during the third quarter valued at about $496,000. Creative Planning boosted its position in shares of United Therapeutics Corp. by 40.2% in the third quarter. Creative Planning now owns 3,379 shares of the biotechnology company’s stock valued at $399,000 after buying an additional 969 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of United Therapeutics Corp. by 1.0% in the third quarter. Fisher Asset Management LLC now owns 3,124 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 32 shares during the period.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.